-
Most Popular
Search Results
240 results for COV
3 Healthcare Acquisitions Google Should Consider
The best way for Google to make an even bigger splash in healthcare is through smart acquisitions like these 3 companies.
I Would Not Be Surprised If SRNE Stock Trades Below $5
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.
There Is More To Pfizer Than The Covid Vaccine
Pfizer is a lot more than the covid vaccine. PFE stock has strong growth potential and is a great dividend stock for 2021.
Inovio Stock Poised for Growth as Preliminary Research Shows Promise
Vaccine trials are in progress, and although it isn’t the only player on the field, Inovio stock has a clear head-start on the competition.
It’s OK to Sell the News on Ocugen and Covaxin
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news.
Novavax Is Looking More Like a Bet Worth Taking
NVAX stock fell behind other vaccine plays early in 2021, but it might not stay behind, There’s lots of evidence to suggest it could move…
3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory
OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward.
Rise with the Vaccine Tide and Buy Norwegian Cruise Line Stock
If you never considered NCLH stock as a “vaccine stock,” it’s time to reconsider your position as cruise-line investments are set to sail.
Sintx Joins List of Highly Speculative Covid-19 Plays
Sintx Technologies stock could be meaningful to investors as it’s one of several smaller companies that offers a way to play the pandemic.
iBio Stock Isn’t the Coronavirus Play Investors Want It to Be
Underscoring the volatility associated with companies purporting to be on the cusps of cures or treatments for international pandemics, IBIO has more than quadrupled just…
Ocugen Looks Very Dicey at Current Levels
Ocugen believes it can distribute 100 million doses of a Covid-19 vaccine in the U.S. But this looks like a long shot for OCGN stock.
Prepare for Another Pop to $15 With Ocugen Stock
Even while Ocugen changes up its strategy in the U.S., the company is pushing for approval elsewhere and OCGN stock can still move higher.
IBIO Stock Is Likely Done in the Covid-19 Race
IBIO stock has continued its volatile swings, this time for the worse. Despite seemingly positive sentiment, it is too far behind to win.
Why iBio Stock May Double or Triple in Value
IBIO stock is a potentially rewarding stock if customers use its manufacturing processes to scale up production of a Covid-19 vaccine.
Turn Out the Lights on iBio’s Covid-19 Vaccine Party
IBIO stock is delivering heartache and more could be on the way as markets realize the company isn’t going to deliver a Covid-19 vaccine.
Go Long Double-Time
Traders should grab their favorite long 2x ETF to prepare for a big move in the Dow.
While Risky, Sorrento Therapeutics Has Many Options to Win
The company does appear to be stretched. But there are still advantages for SRNE stock that make it interesting to investors.
10 – 10 of 240 results
